Diabetic nephropathy
Conditions
Interventions
Febuxostat 10-60mg, once daily, oral
Febuxostat will not be used
Sponsors
Division of Nephrology, Endocrinology and Metabolism, Department of Internal Medicine, Tokai University School of Medicine
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1)Type 2 Diabetes Mellitus 2)Renal function is Moderate 3)Serum uric acid level is 7.0 - 10.0mg/dL in the past six months, patients with no history of gout attack 4)Age 20 years old or older 5)Informed consent was obtained from the patients
Exclusion criteria
Exclusion criteria: 1)Patients with a history of hypersensitivity to febuxostat 2)Patients with secondary hyperuricemia 3)Systolic blood pressure 160 mmHg or higher, or diastolic blood pressure 100 mmHg or more 4)AST or ALT levels are more than double of the normal range 5)Patients who have the following disease were excluded. Non- diabetic chronic kidney disease: glomerulonephritis , renal sclerosis , polycystic kidney disease , inflammatory disease or infection, malignant tumor 6)Patients who develop coronary artery disease , cerebrovascular disease within six months 7)Patients who are administered mercaptopurine hydrate (Roikerin), azathioprine (Imran Azanin) 8)Alcoholics(2 Go / day or more sake in a week average) 9)Patients in Breast-feeding or pregnancy 10)Patients judged by the investigator to be ineligible for some other reason
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The number of podocyte in Urinary(pieces/mL) | — |
Countries
Japan
Contacts
Public ContactWakana Miura
Department of Internal Medicine, Tokai University School of Medicine Division of Nephrology, Endocrinology and Metabolism
Outcome results
None listed